Overview
Sponsored by the American College of Chest Physicians.
Supported by an unrestricted educational grant from Actelion Pharmaceuticals.
Program Description
Pulmonary arterial hypertension (PAH) is a progressive cardiopulmonary vascular disease characterized by right ventricular failure, substantial morbidity, and high mortality. Effective management of PAH is enhanced by earlier recognition and early and aggressive management. This symposium highlights the importance of early recognition and implementation of evidence-based guidelines for the treatment of PAH, as well as addresses future and emerging therapies for PAH. Case presentations and interactive discussion among the faculty emphasize important teaching points.
In this web-based format, participants have the opportunity to obtain the information as it was originally presented by watching the video slide presentations on line, downloading the slides for review, or downloading a written executive summary of the presentations to read. Following their review of the presentations, participants will be asked relevant test questions as part of the evaluation process to obtain CME credit.
Educational Objectives
- Describe the clinical presentation of a patient with PAH, and identify patients who are appropriate for PAH-specific therapy.
- Outline state-of-the-art, evidence-based management approaches for patients with PAH.
- Delineate when and how to escalate therapy in the long-term management of PAH.
- Review future and emerging treatment options for PAH.
Target Audience
Advanced practice nurses, cardiologists, critical care physicians, fellows-in-training, general medicine physicians, physician assistants, pulmonary physicians, registered nurses respiratory therapists
Needs Assessment
Clinicians treating patients with pulmonary hypertension are faced with important questions regarding how to initiate therapy in consideration of current guidelines, what the options are, when to escalate treatment, and what the differences are between various therapeutic agents.
Faculty
Vallerie V. McLaughlin, MD, FCCP
Associate Professor of Medicine
Director, Pulmonary Hypertension Program
University of Michigan Cardiovascular Center
Ann Arbor, MI
Richard N. Channick, MD, FCCP
Professor of Clinical Medicine
Pulmonary and Critical Care Division
University of California San Diego Medical Center
La Jolla, CA
C. Gregory Elliott, MD, FCCP
Chief, Pulmonary, Critical Care, and Sleep Divisions
Director, Pulmonary Hypertension Center of Excellence
LDS Hospital
Chair of Medicine
The University of Utah School of Medicine
Salt Lake City, UT
Harold I. Palevsky, MD, FCCP
Professor of Medicine
Chief, Pulmonary, Allergy, and Critical Care Division
Director, Pulmonary Vascular Disease Program
University of Pennsylvania Health System
Philadelphia, PA
CME & Disclaimers
Release: March 2009
CME Expiration: December 31, 2009
Estimated completion time: 2 hours
This CME product is a Web-based activity. Participants will watch and listen to a Webcast slide presentation, and complete an activity evaluation to obtain CME.
Accreditation - Designation
The American College of Chest Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American College of Chest Physicians designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Anyone who attended the Evidence-Based Treatment of Pulmonary Arterial Hypertension in an Evolving Environment session at CHEST 2008 when this content was presented and already claimed CME for this presentation cannot claim CME from this enduring product.
Disclosure Statement
The ACCP remains strongly committed to providing the best available evidence-based clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of the ACCP to eliminate all situations of potential conflict of interest, but rather to enable those who are working with the ACCP to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the educational activity course director/chair, the Education Committee, or the Conflict of Interest Review Committee to ensure that such situations are properly evaluated and, if necessary, resolved. The ACCP educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all ACCP CME activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available on-site during all educational activities.
The following faculty members of this educational activity have disclosed to the ACCP that a relationship does exist with the respective company/organization as it relates to their presentation of material and should be communicated to the participants of this educational activity:
Vallerie V. McLaughlin, MD, FCCP
Grant monies (from industry-related sources): Actelion, Pfizer, United Therapeutics
Consultant fee, speaker bureau, advisory committee, etc: Actelion, Gilead, Pfizer
Richard N. Channick, MD, FCCP
Grant monies (from industry-related sources): Actelion, Gilead, Lung Rx
Consultant fee, speaker bureau, advisory committee, etc: Actlelion, Gilead
Harold I. Palevsky, MD, FCCP
Consultant fee, speaker bureau, advisory committee, etc: Actelion Pharmaceuticals, CoTherix, Inc. (purchased by Actelion Pharmaceuticals), Myogen, Inc. (purchased by Gilead Sciences), Gilead Sciences
C. Gregory Elliott, MD, FCCP
Employee: Dr. Elliott is currently an employee of Intermountain Healthcare. Intermountain Healthcare currently receives funding from Dr. Elliott's participation as an investigator from Pfizer, Encysive, Actelion, Eli Lilly/ICOS and United Therapeutics.
Consultant fee, speaker bureau, advisory committee, etc: Actelion, LungRx, Encysive, and United Therapeutics (honoraria paid), Pulmonary Hypertension Association board member (travel expenses reimbursed), Steering Committee Member for a PAH Registry sponsored by Actelion, for which he receives reimbursement for his time as a consultant and travel expenses.
Disclaimer
The American College of Chest Physicians (“ACCP”) and its officers, regents, executive committee members, members, related entities, employees, representatives and other agents (collectively, “ACCP Parties”) are not responsible in any capacity for, do not warrant and expressly disclaim all liability for, any content whatsoever in any ACCP publication or other product (in any medium) and the use or reliance on any such content, all such responsibility being solely that of the authors or the advertisers, as the case may be. By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any ACCP publication or other product. Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the ACCP Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.
CME Instructions
CME for this activity is available through December 31, 2009. To receive CME credit and print your certificate, complete an online evaluation:
- Go to www.chestnet.org, and click on the “CME Certificates” icon.
- Log in using your ACCP ID number or e-mail address on file with the ACCP. Enter your ACCP ID number, and click submit, OR, if you do not have an ACCP ID number, click on the link “Create an account here.”
- To locate the product for which you want to claim CME credit, look under the “Available CME” tab on the left navigation bar.
- Click the “Claim Credit” link next to the product to begin the certificate process.
- Complete any required posttest and evaluation. Please be sure to check the box that states you are finished with the evaluation.
- Once you submit the evaluation, your CME certificate will be created and will show under the tab, “My CME History.” You can print it at any time by clicking the “Certificate” link.
If you need help, please contact the CME Administrator via e-mail at CME@chestnet.org, or leave a voice mail message at (847) 498-8376. For faster assistance, please outline the specific problem you are having, and provide your ACCP ID and contact information.
Related Materials
Download a Written Summary (pdf)
Download the Presentation Slides (pdf)
Introduction
Vallerie V. McLaughlin, MD, FCCP
When To Treat PAH: Is Earlier Better?
Richard N. Channick, MD, FCCP
Interactive Case Discussion: When and How To Escalate PAH Therapy
Harold I. Palevsky, MD, FCCP
Interactive Case Discussion: Future Perspectives on PAH
C. Gregory Elliott, MD, FCCP
Search Archives
Search the ACCP archives for CME and non-CME related material. To see our entire archive put a * in the field below and hit search.
Submit Feedback
The ACCP is interested in your feedback concerning A Physician's Perspective®.
